CETP inhibition clings to life as Roche’s dal-OUTCOMES post mortem proves inconclusive
This article was originally published in Scrip
Executive Summary
A shadow continued to fall over cholesterol ester transfer protein (CETP) inhibitors, as the full results of Roche’s doomed dal-OUTCOMES study were presented at the American Heart Association meeting in Los Angeles, suggesting that a small increase in blood pressure with dalcetrapib may have done for the drug